PATENT CLAIM ANALYSIS

Application Number: 16250686
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-08
Patent Classification: ["514", "668000"]

Abstract:
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.

Claim (Index 51):
The method of  claim 43 , wherein the mean C max  of the pharmaceutical composition comprising about 258 mg of amantadine free base equivalent after a single-dose administration is between about 400 and about 1,000 ng/mL.

Metadata:
- Claim Count in Document: 86.0
- Percentile: 99.0
- Lexical Diversity: 1.26087
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16250608', '15898143', '15898148', '16241636', '16241631']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.884842154539788
- 35 USC 102 Novelty (BERT): 0.7300170194045886
- Combined Prediction Score: 0.8693596410262681
- Mean Citation Score: 725.98422
- Max Citation Score: 766.4552
- Similarity Product: 655.3542961536408

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test